Skip to content

Adis in touch

A blog from Adis, a leading global provider of drug information.

Search for:

Recent Posts

Drugs in R&D obtains ESCI indexing
Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI
New health economics book gets airtime
Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer
Baricitinib (Olumiant™): Follow up Approval in Japan (but not yet USA)

Recent Comments

	Adis on Dupilumab (Dupixent®): First G…
	Karen Miller on Dupilumab (Dupixent®): First G…
	Baricitinib (Olumian… on Baricitinib (Olumiant™): First…
	alberttrotter on Sarilumab (Kevzara™): Follow u…
	Sarilumab (Kevzara™)… on Sarilumab (Kevzara™): First Gl…

Archives

August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
October 2016
September 2016
August 2016
July 2016
April 2016
October 2015
July 2015
June 2015
February 2015
October 2014
September 2014
August 2014
July 2014
May 2014
March 2014
January 2014
October 2013
July 2013
January 2012

Categories

Adis (24)
Adis Journals (34)
Adis Pharmacovigilance (12)
AdisInsight (38)

July 5, 2017 2551 × 1914

2.Co-editorsofnewacademicbook

Leave a Reply Cancel reply

Powered by WordPress.com.